Jaka jest cena za Kiromic BioPharma, Inc. (KRBP)

Cena za Kiromic BioPharma, Inc. (KRBP) wynosi $0.11

Jaka jest kapitalizacja rynkowa dla Kiromic BioPharma, Inc. (KRBP)

Kapitalizacja rynkowa dla Kiromic BioPharma, Inc. (KRBP) wynosi $3.62M

Przychody Kiromic BioPharma, Inc. (KRBP)

Kiromic BioPharma, Inc. is a biotechnology enterprise that harnesses artificial intelligence to advance allogeneic cell therapies. The company's core mission involves crafting multi-indication T-cell treatments, specifically engineered to combat solid tumors by leveraging the innate capabilities of Gamma Delta T cells. Its developmental pipeline includes ALEXIS-ISO-1, an allogeneic gamma delta CAR-T cell therapy targeting Isomesothelin, and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy designed to address PD-L1. Supporting its research and development efforts, the company holds licensing agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, maintains a collaborative partnership for R&D with Molipharma, S.R.L., and has established a strategic alliance with Leon Office (H.K.) Ltd. Founded in 2006, the entity was initially known as Kiromic, Inc. before officially changing its name to Kiromic BioPharma, Inc. in December 2019. Its operations are headquartered in Houston, Texas.

Rok	Przychody	Zmień
Za mało danych dla podanych dat.

Rok

Przychody

Zmień

Za mało danych dla podanych dat.

Firma	Przychody	Różnica w przychodach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$10.11B	-	BE

Firma

Przychody

Różnica w przychodach

Kraj